Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03KVW
|
|||
| Former ID |
DIB004268
|
|||
| Drug Name |
MDX-1411
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Medarex Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CD70 antigen (CD27-L) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| RANKL Signaling Pathway | ||||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00730652) Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.